December 26, 2014
2 min read
Save

Latanoprostene bunod effectively reduces IOP

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

A study comparing four concentrations of latanoprostene bunod with latanoprost 0.005% showed that latanoprostene bunod 0.024% led to significantly greater reductions in diurnal IOP than latanoprost.

Perspective from Scott Anthony, OD, FAAO

Weinreb and colleagues randomized 396 adults with open-angle glaucoma or ocular hypertension in one or both eyes to receive latanoprostene bunod 0.006%, 0.012%, 0.024% or 0.040% or latanoprost 0.005% once daily in the evening for 28 days, according to the VOYAGER study results published in the British Journal of Ophthalmology.

“All treatments led to significant reductions in mean diurnal IOP from baseline at all follow-up visits (p < 0.0001 paired t test),” the authors wrote. “Among latanoprostene bunod groups, the IOP reductions were dose-dependent and appeared to plateau with the 0.024% to 0.040% dose.

“Latanoprostene bunod 0.024% led to significantly greater reductions in diurnal IOP compared with latanoprost at the primary endpoint, day 28 (p = 0.005), as well as days 7 (p = 0.033) and 14 (p = 0.015),” they continued.

The authors also stated that the latanoprostene bunod was well tolerated at all concentrations, although associated with slightly more treatment-emergent adverse events overall in the 0.040% treatment group. They noted that a common side effect of glaucoma hypotensive treatment, hyperemia, did not differ across treatments.

“Latanoprostene bunod 0.024% dosed once daily was the lower of the two most effective latanoprostene bunod doses evaluated with significantly greater IOP lowering compared with latanoprost 0.005% solution,” the authors concluded. “To the best of our knowledge, this is the first phase 2 study that demonstrates a drug that is more effective for IOP lowering, without increased ocular hyperemia and with comparable overall side effects, than the commercially available latanoprost 0.005% solution.”

Disclosures: This study was sponsored by Bausch + Lomb. Weinreb received consulting fees from Aerie, Bausch + Lomb, Alcon and Allergan and received grants from Genentech, Heidelberg Engineering, Quark, Nidek, National Eye Institute and Topcon. Sforzolini and Ong are employees of and hold stock from Bausch + Lomb. Vittitow is an employee of Bausch + Lomb. Sing received consulting fees from Allergan, Alcon, Bausch + Lomb and Santen. Kaufman received consulting fees from Bausch + Lomb, Amakem, ONO Pharmaceuticals, Sucampo Pharmaceuticals, Sanofi-Fovea, Merck, Santen Pharmaceuticals, Valeant Pharma, Altheos and Kowa.